Van Le L - Search Results

1

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.

Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ. Clarke-Pearson DL, et al. Among authors: van le l. J Clin Oncol. 2001 Oct 1;19(19):3967-75. doi: 10.1200/JCO.2001.19.19.3967. J Clin Oncol. 2001. PMID: 11579118 Clinical Trial.

2

Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Rose PG, Blessing JA, Van Le L, Waggoner S. Rose PG, et al. Among authors: van le l. Gynecol Oncol. 1998 Aug;70(2):263-6. doi: 10.1006/gyno.1998.5097. Gynecol Oncol. 1998. PMID: 9740702 Clinical Trial.

3

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. Rose PG, et al. Gynecol Oncol. 2000 Aug;78(2):212-6. doi: 10.1006/gyno.2000.5865. Gynecol Oncol. 2000. PMID: 10926805 Clinical Trial.

4

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Miller DS, et al. Among authors: van le l. Am J Clin Oncol. 2000 Aug;23(4):355-7. doi: 10.1097/00000421-200008000-00009. Am J Clin Oncol. 2000. PMID: 10955863 Clinical Trial.

5

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M. Markman M, et al. Among authors: van le l. J Clin Oncol. 2002 May 1;20(9):2365-9. doi: 10.1200/JCO.2002.09.130. J Clin Oncol. 2002. PMID: 11981009 Clinical Trial.

6

Appendix cancer mimicking ovarian cancer.

Gehrig PA, Boggess JF, Ollila DW, Groben PA, Van Le L. Gehrig PA, et al. Among authors: van le l. Int J Gynecol Cancer. 2002 Nov-Dec;12(6):768-72. doi: 10.1046/j.1525-1438.2002.01136.x. Int J Gynecol Cancer. 2002. PMID: 12445258

7

Gemcitabine as a single-agent treatment for ovarian cancer.

Fowler WC Jr, Van Le L. Fowler WC Jr, et al. Among authors: van le l. Gynecol Oncol. 2003 Aug;90(2 Pt 2):S21-3. doi: 10.1016/s0090-8258(03)00340-8. Gynecol Oncol. 2003. PMID: 12928002 Review.

8

Weekly paclitaxel infusion as salvage therapy in ovarian cancer.

Boruta DM 2nd, Fowler WC Jr, Gehrig PA, Boggess JF, Walton LA, Van Le L. Boruta DM 2nd, et al. Among authors: van le l. Cancer Invest. 2003;21(5):675-81. doi: 10.1081/cnv-120023765. Cancer Invest. 2003. PMID: 14628424 Clinical Trial.

9

Uterine serous carcinoma: a comparison of therapy for advanced-stage disease.

Gehrig PA, Morris DE, Van Le L. Gehrig PA, et al. Among authors: van le l. Int J Gynecol Cancer. 2004 May-Jun;14(3):515-20. doi: 10.1111/j.1048-891x.2004.14313.x. Int J Gynecol Cancer. 2004. PMID: 15228426

10

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.

Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. Moore DH, et al. Among authors: van le l. Gynecol Oncol. 2004 Aug;94(2):368-74. doi: 10.1016/j.ygyno.2004.05.033. Gynecol Oncol. 2004. PMID: 15297174

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page